The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management
Open accessAbstract
Epidemiologic and case control population based studies over the past few decades have identified diet as an important determinant of cancer risk. This evidence has kindled an interest into research on bioactive food components and has till date resulted in the identification of many compounds with cancer preventive and therapeutic potential. Among such compounds has been fisetin (3,7,3’,4’-tetrahydroxyflavone), a flavonol and a member of the flavonoid polyphenols that also include quercetin, myricetin and kaempferol. Fisetin is commonly found in many fruits and vegetables such as apples, persimmons, grapes, kiwis, strawberries, onions and cucumbers. We evaluated the effects of fisetin against melanoma and cancers of the prostate, pancreas and the lungs. Using prostate and lung adenocarcinoma cells, we observed that fisetin acts as a dual inhibitor of the PI3K/Akt and the mTOR pathways. This is a significant finding considering the fact that mTOR is phosphorylated and its activation is more frequent in tumors with overexpression of PI3K/Akt. Dual inhibitors of PI3K/Akt and mTOR signaling have been suggested as valuable agents for treating such cancers. Here, we summarize our findings on the dietary flavonoid fisetin and its effects on cancer with particular focus on prostate cancer. Our observations and findings from other laboratories suggest that fisetin could be a useful chemotherapeutic agent that could be used either alone or as an adjuvant with conventional chemotherapeutic drugs for the management of prostate and other cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Cancer chemoprevention with dietary phytochemicals
Surh, Y.-J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1189 · Cited by 2,955
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Research works printed but not linked: 45
- Khan, 2008, Cancer chemoprevention through dietary antioxidants: progress and promise, Antioxid Redox Signal, 10, 475, 10.1089/ars.2007.1740 · DOI · Paper page
- Moon, 2006, Dietary flavonoids: effects on xenobiotic and carcinogen metabolism, Toxicol In Vitro, 20, 187, 10.1016/j.tiv.2005.06.048 · DOI · Paper page
- Kimira, 1998, Japanese intake of flavonoids and isoflavonoids from foods, J Epidemiol, 8, 168, 10.2188/jea.8.168 · DOI · Paper page
- Shia, 2009, Metabolism and pharmacokinetics of 3,3′,4′,7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites, J Agric Food Chem, 57, 83, 10.1021/jf802378q · DOI
- Maher, 2007, A novel approach to screening for new neuroprotective compounds for the treatment of stroke, Brain Res, 1173, 117, 10.1016/j.brainres.2007.07.061 · DOI
- Ishige, 2001, Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms, Free Radic Biol Med, 30, 433, 10.1016/S0891-5849(00)00498-6 · DOI · Paper page
- Gabor, 1966, Antibacterial effect of fisetin and fisetinidin, Nature, 212, 1273, 10.1038/2121273a0 · doi:10.1038/2121273a0
- Sagara, 2004, Induction of PC12 cell differentiation by flavonoids is dependent upon extracellular signal-regulated kinase activation, J Neurochem, 90, 1144, 10.1111/j.1471-4159.2004.02563.x · DOI
- Maher, 2006, Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory, Proc Natl Acad Sci USA, 103, 16568, 10.1073/pnas.0607822103 · DOI · Paper page
- Zheng, 2008, Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity, Int Immunopharmacol, 8, 484, 10.1016/j.intimp.2007.12.012 · DOI · Paper page
- Sung, 2007, Mol Pharmacol, 71, 1703, 10.1124/mol.107.034512 · DOI · Paper page
- Touil, 2009, Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization, Nutr Cancer, 61, 310, 10.1080/01635580802521346 · DOI
- Salmela, 2009, Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint, Carcinogenesis, 30, 1032, 10.1093/carcin/bgp101 · DOI
- Chen, 2002, Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1, Arch Toxicol, 76, 351, 10.1007/s00204-002-0346-6 · DOI · Paper page
- Lee, 2002, Wogonin and fisetin induce apoptosis in human promyeloleukemic cells, accompanied by a decrease of reactive oxygen species, and activation of caspase 3 and Ca(2+)-dependent endonuclease, Biochem Pharmacol, 63, 225, 10.1016/S0006-2952(01)00876-0 · DOI · Paper page
- Liao, 2009, Involvement of the ERK signaling pathway in fisetin reduces invasion and migration in the human lung cancer cell line A549, J Agric Food Chem, 57, 8933, 10.1021/jf902630w · DOI
- Ravichandran, 2011, Fisetin, a novel flavonol attenuates benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice, Food Chem Toxicol, 49, 1141, 10.1016/j.fct.2011.02.005 · DOI
- Suh, 2009, A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways, Carcinogenesis, 30, 300, 10.1093/carcin/bgn269 · DOI · Paper page
- Chen, 2010, Enhancement of p53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetin, Int J Radiat Oncol Biol Phys, 77, 1527, 10.1016/j.ijrobp.2010.02.043 · doi:10.1016/j.ijrobp.2010.02.043
- Lu, 2005, Fisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells, J Nutr, 135, 2884, 10.1093/jn/135.12.2884 · DOI
- Yu, 2011, Securin depletion sensitizes human colon cancer cells to fisetin-induced apoptosis, Cancer Lett, 300, 96, 10.1016/j.canlet.2010.09.015 · doi:10.1016/j.canlet.2010.09.015
- Murtaza, 2009, Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB, Int J Cancer, 125, 2465, 10.1002/ijc.24628 · DOI
- Hiipakka, 2002, Structure–activity relationships for inhibition of human 5alpha-reductases by polyphenols, Biochem Pharmacol, 63, 1165, 10.1016/S0006-2952(02)00848-1 · DOI · Paper page
- Haddad, 2010, Antiproliferative mechanisms of the flavonoids 2,2′-dihydroxychalcone and fisetin in human prostate cancer cells, Nutr Cancer, 62, 668, 10.1080/01635581003605524 · DOI
- Afaq, 2008, Inhibition of epidermal growth factor receptor signaling pathway by delphinidin, an anthocyanidin in pigmented fruits and vegetables, Int J Cancer, 123, 1508, 10.1002/ijc.23675 · doi:10.1002/ijc.23675
- Khan, 2008, Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells, Carcinogenesis, 29, 1049, 10.1093/carcin/bgn078 · DOI · Paper page
- Khan, 2008, A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice, Cancer Res, 68, 8555, 10.1158/0008-5472.CAN-08-0240 · DOI · Paper page
- Chien, 2010, Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells, Mol Cell Biochem, 333, 169, 10.1007/s11010-009-0217-z · DOI
- Suh, 2010, Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells, Carcinogenesis, 31, 1424, 10.1093/carcin/bgq115 · DOI · Paper page
- Malik, 2002, Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer, Clin Cancer Res, 8, 1168
- McMenamin, 1999, Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage, Cancer Res, 59, 4291
- Kremer, 2006, Expression of mTOR signaling pathway markers in prostate cancer progression, Prostate, 66, 1203, 10.1002/pros.20410 · DOI · Paper page
- Gioeli, 2005, Signal transduction in prostate cancer progression, Clin Sci (Lond), 108, 293, 10.1042/CS20040329 · DOI
- Gioeli, 1999, Activation of mitogen-activated protein kinase associated with prostate cancer progression, Cancer Res, 59, 279
- Abreu-Martin, 1999, Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer, Mol Cell Biol, 19, 5143, 10.1128/MCB.19.7.5143 · DOI · Paper page
- Gao, 2006, Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer, Proc Natl Acad Sci USA, 103, 14477, 10.1073/pnas.0606836103 · DOI · Paper page
- Uzgare, 2004, Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells, Cancer Res, 64, 6190, 10.1158/0008-5472.CAN-04-0968 · DOI
- Kinkade, 2008, Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model, J Clin Invest, 118, 3051
- Khan, 2012, Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin, Int J Cancer, 130, 1695, 10.1002/ijc.26178 · DOI
- Dowling, 2010, mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs, Science, 328, 1172, 10.1126/science.1187532 · DOI · Paper page
- Webber, 2001, Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression, Prostate, 47, 1, 10.1002/pros.1041 · DOI
- Tripathi, 2011, Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors, Mol Cancer Ther, 10, 255, 10.1158/1535-7163.MCT-10-0606 · DOI
- Kandaswami, 1993, Ascorbic acid-enhanced antiproliferative effect of flavonoids on squamous cell carcinoma in vitro, Anticancer Drugs, 4, 91, 10.1097/00001813-199302000-00012 · DOI
- Touil, 2011, Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice, Cancer Chemother Pharmacol, 68, 445, 10.1007/s00280-010-1505-8 · DOI
- Szliszka, 2011, The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells, Int J Oncol, 39, 771
Cited by
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Fisetin is a senotherapeutic that extends health and lifespan
Yousefzadeh, M. J., Zhu, Y., McGowan, S. J., Angelini, L., Fuhrmann-Stroissnigg, H., Xu, M., Ling, Y. Y., Melos, K. I., Pirtskhalava, T., Inman, C. L., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.015 · Cited by 1,032
Fisetin: A Dietary Antioxidant for Health Promotion
Khan, N., Syed, D. N., Ahmad, N., & Mukhtar, H. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4901 · Cited by 506
Self-citationAgeing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
A Starring Role for Stellate Cells in the Pancreatic Cancer Microenvironment
Apte, M. V., Wilson, J. S., Lugea, A., & Pandol, S. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.11.037 · Cited by 450
Metadata
- Authors
- Adhami, V. M., Syed, D. N., Khan, N., & Mukhtar, H.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 84
- Issue
- 10
- Pages
- 1277-1281
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2036380534
- Cited by
- 186
- References
- 3
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- United States Public Health Service (RO1 CA 160867)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. https://app.cochat.ai/papers/10.1016/j.bcp.2012.07.012
- The paper
- Adhami, V. M., Syed, D. N., Khan, N., & Mukhtar, H. (2012). Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2012.07.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.